Previous close | 0.6500 |
Open | 0.6450 |
Bid | 0.0000 x N/A |
Ask | 0.7200 x N/A |
Day's range | 0.6450 - 0.6600 |
52-week range | 0.4460 - 2.5000 |
Volume | |
Avg. volume | 282 |
Market cap | 85.921M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -55.7400 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LONDON, March 25, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.
LONDON, March 20, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family. The Company is pleased to announce the appointment of Dr. James Malone as BenevolentAI’s new Chief Technology Officer. James will j
LONDON, March 20, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of its Annual Report and Accounts for the year ended 31 December 2023 (the "2023 Annual Report") and the convening notice for its annual general meeting to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the "2024 AGM") (the "2024 AGM Notice"